
|Articles|May 10, 2004
Botulinum toxin shows promising results in refractory OAB
Known primarily for smoothing facial wrinkles, botulinumtoxin A (Botox) is gaining acceptance as a treatment option for refractoryoveractive and neurogenic bladder. The latest evidence comes from the Universityof Pittsburgh School of Medicine, where a 110-patient review of the off-labeluse of botulinum toxin for those indications produced promising resultsin terms of both safety and efficacy.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves capivasertib plus abiraterone and prednisone for PTEN-deficient mHSPC
2
Toni Choueiri, MD, reacts to FDA approval of adjuvant belzutifan with pembrolizumab for ccRCC
3
Dean Elterman, MD, highlights efficacy and safety data on the Zenflow Prostatic Spring
4
FDA approves adjuvant belzutifan with pembrolizumab for ccRCC
5






